Identification and mitigation of a reactive metabolite liability associated with aminoimidazoles

Chemical Research in Toxicology

Volumn 27, Issue 9, 2014, Pages 1586-1597

  Srivastava, Abhishek ^a   Ramachandran, Sreekanth ^a   Hameed, Shahul P ^a   Ahuja, Vijay Kamal ^a   Hosagrahara, Vinayak P ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMINOIMIDAZOLE DERIVATIVE; BENZIMIDAZOLE; EPOXIDE; GLUTATHIONE; IMIDAZOLE DERIVATIVE; IMINE; METHYL GROUP; QUINONE DERIVATIVE; UNCLASSIFIED DRUG; BENZIMIDAZOLE DERIVATIVE; HETEROCYCLIC COMPOUND;

ARTICLE; DRUG IDENTIFICATION; DRUG METABOLISM; EPOXIDATION; HUMAN; INCUBATION TIME; LIVER MICROSOME; METABOLITE; NONHUMAN; RAT; ANIMAL; CHEMISTRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; TANDEM MASS SPECTROMETRY;

RATTUS;

ANIMALS; AZA COMPOUNDS; BENZIMIDAZOLES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; IMINES; QUINONES; RATS; TANDEM MASS SPECTROMETRY;

EID: 84918501106     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx500212c     Document Type: Article

References (31)

1. Kola, I., and Landis, J. (2004) Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discovery 3, 711-716.
2. Lasser, K. E., and Allen., P. D., Woolhandler, S. J., Himmelstein, D. U., Wolfe, S. M., and Bor, D. H. (2002) Timing of new black box warnings and withdrawals for prescription medications. JAMA 287, 2215-2220.
3. Uetrecht, J. (2008) Idiosyncratic drug reactions: past, present, and future. Chem. Res. Toxicol. 21, 84-92.
4. Smith, D. A., and Obach, R. S. (2006) Metabolites and safety: what are the concerns, and how should we address them? Chem. Res. Toxicol. 19, 1570-1579.
5. Uetrecht, J. (2006) Evaluation of which reactive metabolite, if any, is responsible for a specific idiosyncratic reaction. Drug Metab. Rev. 38, 745-753.
6. Guengerich, F. P. (2006) Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J. 8, E101-E111.
7. Park, B. K., and Kitteringham., N. R., Maggs, J. L., Pirmohamed, M., and Williams, D. P. (2005) The role of metabolic activation in drug-induced hepatotoxicity. Annu. Rev. Pharmacol. Toxicol. 45, 177-202.
8. Park, B. K., Boobis, A., Clarke, S., Goldring, C. E., Jones, D., Kenna, J. G., Lambert, C., Laverty, H. G., Naisbitt, D. J., Nelson, S., Nicoll-Griffith, D. A., Obach, R. S., Routledge, P., Smith, D. A., Tweedie, D. J., Vermeulen, N., Williams, D. P., Wilson, I. D., and Baillie, T. A. (2011) Managing the challenge of chemically reactive metabolites in drug development. Nat. Rev. Drug Discovery 10, 292-306.
9. Stachulski, A. V., and Baillie., T. A., Kevin Park, B., Scott Obach, R., Dalvie, D. K., Williams, D. P., Srivastava, A., Regan, S. L., Antoine, D. J., Goldring, C. E. P., Chia, A. J. L., Kitteringham, N. R., Randle, L. E., Callan, H., Castrejon, J. L., Farrell, J., Naisbitt, D. J., and Lennard, M. S. (2013) The generation, detection, and effects of reactive drug metabolites. Med. Res. Rev. 33, 985-1080.
10. Zhang, L., and Peng., X. M., Damu, G. L. V., Geng, R. X., and Zhou, C. H. (2014) Comprehensive review in current developments of imidazole-based medicinal chemistry. Med. Res. Rev. 34, 340-437.
11. Boiani, M., and Gonzalez, M. (2005) Imidazole and benzimidazole derivatives as chemotherapeutic agents. Mini. Rev. Med. Chem. 5, 409-424.
12. El Rashedy, A. A., and Aboul-Enein, H. Y. (2013) Benzimidazole derivatives as potential anticancer agents. Mini. Rev. Med. Chem. 13, 399-407.
13. Hosagrahara, V., Reddy, J., Ganguly, S., Panduga, V., Ahuja, V., Parab, M., and Giridhar, J. (2013) Effect of repeated dosing on rifampin exposure in BALB/c mice. Eur. J. Pharm. Sci. 49, 33-38.
14. Scholz, K., Dekant, W., Volkel, W., and Pahler, A. (2005) Rapid detection and identification of N-acetyl-L-cysteine thioethers using constant neutral loss and theoretical multiple reaction monitoring combined with enhanced product-ion scans on a linear ion trap mass spectrometer. J. Am. Soc. Mass Spectrom. 16, 1976-1984.
15. Srivastava, A., and Lian., L. Y., Maggs, J. L., Chaponda, M., Pirmohamed, M., and Williams., D. P., and Park, B. K. (2010) Quantifying the metabolic activation of nevirapine in patients by integrated applications of NMR and mass spectrometries. Drug Metab. Dispos. 38, 122-132.
16. Srivastava, A., and Maggs., J. L., Antoine, D. J., Williams, D. P., Smith, D. A., and Park, B. K. (2010) Role of Reactive Metabolites in Drug-Induced Hepatotoxicity, In Adverse Drug Reactions (Uetrecht, J., ed.) pp 165-194, Springer, Berlin, Germany.
17. Argoti, D., Liang, L., Conteh, A., Chen, L., Bershas, D., Yu, C. P., Vouros, P., and Yang, E. (2005) Cyanide trapping of iminium ion reactive intermediates followed by detection and structure identification using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Chem. Res. Toxicol. 18, 1537-1544.
18. Evans, D. C., and Watt., A. P., Nicoll-Griffith, D. A., and Baillie, T. A. (2004) Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol. 17, 3-16.
19. Kalgutkar, A. S., and Soglia, J. R. (2005) Minimising the potential for metabolic activation in drug discovery. Expert. Opin. Drug Metab. Toxicol. 1, 91-142.
20. Lau, S. S., and Abrams., G. D., and Zannoni, V. G. (1980) Metabolic activation and detoxification of bromobenzene leading to cytotoxicity. J. Pharmacol. Exp. Ther. 214, 703-708.
21. Zampaglione, N., and Jollow., D. J., Mitchell, J. R., Stripp, B., Hamrick, M., and Gillette, J. R. (1973) Role of detoxifying enzymes in bromobenzene-induced liver necrosis. J. Pharmacol. Exp. Ther. 187, 218-227.
22. Wen, B., and Fitch, W. L. (2009) Analytical strategies for the screening and evaluation of chemically reactive drug metabolites. Expert Opin. Drug Metab. Toxicol. 5, 39-55.
23. Zhang, K. E., and Naue., J. A., Arison, B., and Vyas, K. P. (1996) Microsomal metabolism of the 5-lipoxygenase inhibitor L-739, 010: evidence for furan bioactivation. Chem. Res. Toxicol. 9, 547-554.
24. Dansette, P. M., Bertho, G., and Mansuy, D. (2005) First evidence that cytochrome P450 may catalyze both S-oxidation and epoxidation of thiophene derivatives. Biochem. Biophys. Res. Commun. 338, 450-455.
25. Peterson, L. A. (2006) Electrophilic intermediates produced by bioactivation of Furan. Drug Metab. Rev. 38, 615-626.
26. Hutzler, J. M., and Steenwyk., R. C., Smith, E. B., Walker, G. S., and Wienkers, L. C. (2004) Mechanism-based inactivation of cytochrome P450 2D6 by 1-[(2-ethyl-4-methyl-1H-imidazol-5-yl)methyl]- 4-[4-(trifluoromethyl)-2-pyridinyl]piperazine: kinetic characterization and evidence for apoprotein adduction. Chem. Res. Toxicol. 17, 174-184.
27. Obach, R. S., and Kalgutkar., A. S., Ryder, T. F., and Walker, G. S. (2008) In vitro metabolism and covalent binding of enol-carboxamide derivatives and anti-inflammatory agents sudoxicam and meloxicam: insights into the hepatotoxicity of sudoxicam. Chem. Res. Toxicol. 21, 1890-1899.
28. Bolton, J. L., and Trush., M. A., Penning, T. M., Dryhurst, G., and Monks, T. J. (2000) Role of quinones in toxicology. Chem. Res. Toxicol. 13, 135-160.
29. Li, X., and Kamenecka., T. M., and Cameron, M. D. (2009) Bioactivation of the epidermal growth factor receptor inhibitor gefitinib: implications for pulmonary and hepatic toxicities. Chem. Res. Toxicol. 22, 1736-1742.
30. Driscoll, J. P., Aliagas, I., Harris, J. J., Halladay, J. S., Khatib-Shahidi, S., Deese, A., Segraves, N., and Khojasteh-Bakht, S. C. (2010) Formation of a quinoneimine intermediate of 4-fluoro-N-methylani-line by FMO1: carbon oxidation plus defluorination. Chem. Res. Toxicol. 23, 861-863.
31. Dalvie, D., Kang, P., Loi, C. M., Goulet, L., and Nair, S. (2010) Chapter 7 Influence of Heteroaromatic Rings on ADME Properties of Drugs, in Metabolism, Pharmacokinetics and Toxicity of Functional Groups: Impact of Chemical Building Blocks on ADMET, pp 328-369, The Royal Society of Chemistry, Cambridge, U.K.